MétaCan
Menu
← Back to cohort

Circulating tumor DNA as a minimal residual disease assessment and recurrence risk in hepatocellular carcinoma: A systematic review and meta-analysis.

2025· review· en· W4410817399 on OpenAlexaff
Isabella Romagnoli Buonopane, Erick Figueiredo Saldanha, Junior Samuel Alonso de Menezes, Renata D’Alpino Peixoto, Tiago Biachi De Castria, Camila Mariana de Paiva De Paiva Reis, Lucas Diniz da Conceição, Luís Felipe Leite

Bibliographic record

VenueJournal of Clinical Oncology · 2025
Typereview
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicCancer Genomics and Diagnostics
Canadian institutionsBC Cancer AgencyPrincess Margaret Cancer Centre
Fundersnot available
KeywordsMedicineHepatocellular carcinomaMeta-analysisOncologyMinimal residual diseaseInternal medicineDiseaseResidualCirculating tumor DNACarcinomaRadiologyCancer

Abstract

fetched live from OpenAlex

e15055 Background: Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the mainstay of curative treatment for patients (pts) with HCC confined to the liver remains hepatectomy, thermal ablation, or liver transplantation. However, despite these approaches, cancer relapses are still high and strongly correlated with the presence of residual disease following curative-intent treatment. Hence, endeavours to refine risk stratification and identify pts more likely to recur is critical. To this end, circulating tumour DNA (ctDNA) is promising. This meta-analysis seeks to assess the prognostic role of plasma ctDNA in pts diagnosed with HCC undergoing curative treatment. Methods: A systematic search of MEDLINE, EMBASE, and Cochrane databases up to November 2024 was carried out to identify studies investigating plasma ctDNA collection in pts with early or intermediate- stage Barcelona Clinic Liver Cancer (BCLC) HCC undergoing curative-intent treatment, baseline (before radical treatment) and landmark time points (after radical treatment). The hazards ratios (HRs) with 95% confidence intervals (CIs) were pooled for recurrence- free survival (RFS) and overall survival (OS) using a random-effects model. Results: A total of 10 retrospective studies, encompassing 928 pts with plasma samples available at baseline and landmark timepoints, were included. Plasma samples were obtained up to 12 weeks postoperatively. Six studies utilized a tumor-informed approach for ctDNA analysis, 2 employed a tumor-agnostic approach, and 1 incorporated a combined analysis of both methods. ctDNA detection varied, with 6 studies using next-generation sequencing (NGS) and 3 using NGS combined with droplet digital polymerase chain reaction (ddPCR). Pts with detectable postoperative ctDNA had significantly shorter RFS compared to those with undetectable ctDNA levels (HR: 4.48, 95% CI [2.46, 8.16]; I² = 80%, p < 0.001). Baseline ctDNA detection was significantly associated with shorter RFS (HR 4.71, 95% CI [2.35–9.41]; I² = 0%, p < 0.001). Likewise, ctDNA positivity at the landmark time point correlated with reduced OS (HR 2.99, 95% CI [1.94–4.61]; I² = 47%, p < 0.001). Four studies with available data were analyzed, with sensitivities ranging from 33% to 82% and specificities ranging from 41% to 100%, highlighting variability in diagnostic performance across studies. Leave-one-out analysis confirms ctDNA's prognostic value for higher RFS (HR 4.48, 95% CI [2.48–8.16]) without any study disproportionately influencing results. Conclusions: The detection of ctDNA following curative-intent treatment in pts with early-stage HCC was prognostic. There is potential to leverage plasma ctDNA in prospective studies, which may improve risk stratification and aid treatment selection.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.009
metaresearch head score (Gemma)0.020
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: Meta-analysis
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.013
Threshold uncertainty score0.049

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0090.020
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0130.028
Bibliometrics0.0060.007
Science and technology studies0.0000.001
Scholarly communication0.0020.001
Open science0.0020.001
Research integrity0.0020.001
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.136
GPT teacher head0.476
Teacher spread0.339 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicCancer Genomics and Diagnostics→French-language works237,207→